Cantargia AB (CHIX:CANTAS) Short Percentage of Float


CHIX:CANTAS Cantargia AB CHIX:CANTAS
37 GF Score
Price kr4.17
! 2 Warning Signs
View Full Analysis

What is Cantargia AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CHIX:CANTAS vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Cantargia AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantargia AB Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Cantargia AB's Short Percentage of Float falls into.


CHIX:CANTAS
37GF Score
Cantargia AB CHIX:CANTAS
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB Business Description

Other Exchanges CANTA:Sweden7V3:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score

Get the complete analysis for CHIX:CANTAS

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.17
Price